Lisdexamfetamine Dimesylate Capsule Shortage: Current Availability and Manufacturer Updates
According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.
Lisdexamfetamine Dimesylate capsules are currently experiencing supply disruptions, with several manufacturers reporting limited availability or active ingredient shortages through early 2026.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on February 11, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — Drug Shortages — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Lisdexamfetamine Dimesylate) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What's in Shortage
Drug Name: Lisdexamfetamine Dimesylate Capsule
Brand Name: LISDEXAMFETAMINE DIMESYLATE
Dosage Form: Capsule (10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg)
Therapeutic Category: Psychiatry
Current Status: Current Shortage
Initial Posting Date: 07/14/2023
Last Updated: 02/04/2026
Which Manufacturers Are Affected
Supply status varies significantly by manufacturer and dosage strength:
- Alvogen: All strengths (10 mg - 70 mg) are currently Available. (Contact: 844-842-8672 / CustomerService-US@alvogen.com)
- Amneal Pharmaceuticals: All presentations (20 mg - 70 mg) are Unavailable due to active ingredient shortages. (Contact: 866-525-7270)
- Elite Laboratories, Inc.: All strengths (10 mg - 70 mg) are under Limited Availability. (Contact: 888-852-6657)
- Sun Pharmaceutical Industries, Inc.: All strengths (10 mg - 70 mg) are under Limited Availability, with additional supply anticipated in Q1 2026. (Contact: 800-818-4555)
- SpecGx LLC: All strengths (10 mg - 70 mg) are under Limited Availability and are being placed on allocation to customers. (Contact: 800-325-8888)
- Teva Pharmaceuticals USA, Inc.: Status varies by strength. Some are available, while others are under limited availability with estimated recovery dates in February or March 2026. (Contact: 800-545-8800)
- Lannett Company, Inc.: Mixed status. Some strengths (50 mg, 60 mg) are available, while others (10 mg, 70 mg) are unavailable or limited. (Contact: 844-834-0530)
- Mylan Pharmaceuticals Inc. (Viatris): Mixed status. Strengths 10 mg, 30 mg, 50 mg, and 70 mg are available; 20 mg, 40 mg, and 60 mg are unavailable. (Contact: 800-796-9526)
Why There's a Shortage
Several manufacturers, including Amneal and Mylan, have cited a shortage of an active ingredient as the reason for supply disruptions. Other manufacturers have reported limited availability or customer allocation without specifying a primary cause. Recovery for several impacted lines is estimated for the first quarter of 2026.
What Patients Should Do
If you are affected by this shortage, please consider the following steps:
- Consult Your Healthcare Provider: Discuss your treatment plan and potential alternatives with your doctor. Do not make changes to your medication without medical supervision.
- Speak with Your Pharmacist: Pharmacists may have information on which specific strengths or manufacturers are currently in stock at their location.
- Contact Manufacturers: You may use the contact information provided above to inquire about the availability of specific National Drug Codes (NDCs).
Disclaimer: This information is for educational purposes only. Patients should always consult with their healthcare provider regarding medical decisions and treatment options.
Source
FDA Drug Shortage Database
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.
What is this FDA drug-shortage notice about? ▾
Which agency issued this alert? ▾
How severe is this alert? ▾
What area is affected? ▾
Where can I find more Drug Shortages updates? ▾
Primary source data
EPA Outdoor Air Quality Data
Federal monitoring network — every measurement we report
AirNow (EPA / NOAA)
Real-time AQI for every monitored U.S. location
National Weather Service
Active watches, warnings, and advisories — NOAA
CDC Air Quality & Health
Health-impact reference behind every AQI category